Cargando…
High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status
BACKGROUND: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in these molecular subtypes and its impact on clinical outcome,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724316/ https://www.ncbi.nlm.nih.gov/pubmed/31481117 http://dx.doi.org/10.1186/s40425-019-0712-z |
_version_ | 1783448965905121280 |
---|---|
author | Kortekaas, Kim E. Santegoets, Saskia J. Abdulrahman, Ziena van Ham, Vanessa J. van der Tol, Marij Ehsan, Ilina van Doorn, Helena C. Bosse, Tjalling van Poelgeest, Mariëtte I. E. van der Burg, Sjoerd H. |
author_facet | Kortekaas, Kim E. Santegoets, Saskia J. Abdulrahman, Ziena van Ham, Vanessa J. van der Tol, Marij Ehsan, Ilina van Doorn, Helena C. Bosse, Tjalling van Poelgeest, Mariëtte I. E. van der Burg, Sjoerd H. |
author_sort | Kortekaas, Kim E. |
collection | PubMed |
description | BACKGROUND: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in these molecular subtypes and its impact on clinical outcome, an in-depth study of the tumor immune microenvironment was performed. METHODS: Sixty-five patients with invasive VSCC matched for age, FIGO stage and treatment modality, were grouped according to the presence of HPV and p53 protein expression status. Archived tissues were analyzed for intraepithelial and stromal expression of CD3, CD8, Foxp3, PD-1, and pan-keratin in randomly selected areas using immunofluorescence. Additional phenotyping of T cells was performed ex-vivo on VSCC (n = 14) and blood samples by flow cytometry. Healthy vulvar samples and blood served as controls. RESULTS: Based on T-cell infiltration patterns about half of the VSCC were classified as inflamed or altered-excluded while one-third was immune-deserted. High intraepithelial helper T cell infiltration was observed in 78% of the HPV-induced VSCC, 60% of the HPVnegVSCC/p53wildtype and 40% of the HPVnegVSCC with abnormal p53 expression. A high intraepithelial infiltration with activated (CD3(+)PD-1(+)), specifically helper T cells (CD3(+)CD8(−)Foxp3(−)), was associated with a longer recurrence-free period and overall survival, irrespective of HPV and p53 status. Flow cytometry confirmed the tumor-specific presence of activated (CD4(+)PD-1(++)CD161(−)CD38(+)HLA-DR(+) and CD8(+)CD103(+)CD161(−)NKG2A(+/−)PD1(++)CD38(++)HLA-DR(+)) effector memory T cells. CONCLUSION: This is the first study demonstrating an association between intraepithelial T cells and clinical outcome in VSCC. Our data suggest that abnormal p53 expressing VSCCs mostly are cold tumors whereas HPV-driven VSCCs are strongly T-cell infiltrated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0712-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6724316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67243162019-09-10 High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status Kortekaas, Kim E. Santegoets, Saskia J. Abdulrahman, Ziena van Ham, Vanessa J. van der Tol, Marij Ehsan, Ilina van Doorn, Helena C. Bosse, Tjalling van Poelgeest, Mariëtte I. E. van der Burg, Sjoerd H. J Immunother Cancer Research Article BACKGROUND: Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune infiltrate in these molecular subtypes and its impact on clinical outcome, an in-depth study of the tumor immune microenvironment was performed. METHODS: Sixty-five patients with invasive VSCC matched for age, FIGO stage and treatment modality, were grouped according to the presence of HPV and p53 protein expression status. Archived tissues were analyzed for intraepithelial and stromal expression of CD3, CD8, Foxp3, PD-1, and pan-keratin in randomly selected areas using immunofluorescence. Additional phenotyping of T cells was performed ex-vivo on VSCC (n = 14) and blood samples by flow cytometry. Healthy vulvar samples and blood served as controls. RESULTS: Based on T-cell infiltration patterns about half of the VSCC were classified as inflamed or altered-excluded while one-third was immune-deserted. High intraepithelial helper T cell infiltration was observed in 78% of the HPV-induced VSCC, 60% of the HPVnegVSCC/p53wildtype and 40% of the HPVnegVSCC with abnormal p53 expression. A high intraepithelial infiltration with activated (CD3(+)PD-1(+)), specifically helper T cells (CD3(+)CD8(−)Foxp3(−)), was associated with a longer recurrence-free period and overall survival, irrespective of HPV and p53 status. Flow cytometry confirmed the tumor-specific presence of activated (CD4(+)PD-1(++)CD161(−)CD38(+)HLA-DR(+) and CD8(+)CD103(+)CD161(−)NKG2A(+/−)PD1(++)CD38(++)HLA-DR(+)) effector memory T cells. CONCLUSION: This is the first study demonstrating an association between intraepithelial T cells and clinical outcome in VSCC. Our data suggest that abnormal p53 expressing VSCCs mostly are cold tumors whereas HPV-driven VSCCs are strongly T-cell infiltrated. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0712-z) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-03 /pmc/articles/PMC6724316/ /pubmed/31481117 http://dx.doi.org/10.1186/s40425-019-0712-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kortekaas, Kim E. Santegoets, Saskia J. Abdulrahman, Ziena van Ham, Vanessa J. van der Tol, Marij Ehsan, Ilina van Doorn, Helena C. Bosse, Tjalling van Poelgeest, Mariëtte I. E. van der Burg, Sjoerd H. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status |
title | High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status |
title_full | High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status |
title_fullStr | High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status |
title_full_unstemmed | High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status |
title_short | High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status |
title_sort | high numbers of activated helper t cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of hpv or p53 status |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724316/ https://www.ncbi.nlm.nih.gov/pubmed/31481117 http://dx.doi.org/10.1186/s40425-019-0712-z |
work_keys_str_mv | AT kortekaaskime highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT santegoetssaskiaj highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT abdulrahmanziena highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT vanhamvanessaj highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT vandertolmarij highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT ehsanilina highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT vandoornhelenac highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT bossetjalling highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT vanpoelgeestmarietteie highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status AT vanderburgsjoerdh highnumbersofactivatedhelpertcellsareassociatedwithbetterclinicaloutcomeinearlystagevulvarcancerirrespectiveofhpvorp53status |